L 659989 | CAS#129314-27-8 | Platelet activating factor receptor antagonist

MedKoo Cat#: 596613 | Name: L 659989

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L 659989 is a Platelet activating factor receptor antagonist.

Chemical Structure

L 659989

CAS#129314-27-8

Theoretical Analysis

MedKoo Cat#: 596613

Name: L 659989

CAS#: 129314-27-8

Chemical Formula: C24H32O8S

Exact Mass: 480.1818

Molecular Weight: 480.57

Elemental Analysis: C, 59.98; H, 6.71; O, 26.63; S, 6.67

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

L 659989; L-659989; L659989; L-659,989; L 659,989; L659,989;

IUPAC/Chemical Name

2-(3-methoxy-5-(methylsulfonyl)-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran

InChi Key

NZWPFJNQOZFEDT-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H32O8S/c1-7-10-31-24-21(29-4)13-16(14-22(24)33(6,25)26)18-9-8-17(32-18)15-11-19(27-2)23(30-5)20(12-15)28-3/h11-14,17-18H,7-10H2,1-6H3

SMILES Code

COC1=C(OC)C(OC)=CC(C2CCC(C3=CC(S(=O)(C)=O)=C(OCCC)C(OC)=C3)O2)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 480.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Birk-Sørensen L, Kerrigan CL, Wang C. Platelet activating factor antagonism in pure skin flaps exposed to ischaemia-reperfusion injury. Scand J Plast Reconstr Surg Hand Surg. 1999 Jun;33(2):155-61. PubMed PMID: 10450571. 2: Gómez-Muñoz A, O'Brien L, Steinbrecher UP. The platelet-activating factor receptor antagonist L-659,989 inhibits phospholipase D activity. Biochim Biophys Acta. 1999 May 18;1438(2):247-52. PubMed PMID: 10320807. 3: Stotland MA, Kerrigan CL. The role of platelet-activating factor in musculocutaneous flap reperfusion injury. Plast Reconstr Surg. 1997 Jun;99(7):1989-99; discussion 2000-1. PubMed PMID: 9180723. 4: Herbertson MJ, Werner HA, Walley KR. Platelet-activating factor antagonism improves ventricular contractility in endotoxemia. Crit Care Med. 1997 Feb;25(2):221-6. PubMed PMID: 9034254. 5: Gallego MJ, Zoja C, Morigi M, Micheletti G, Imberti B, Foppolo M, Remuzzi A, Remuzzi G. Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. Am J Kidney Dis. 1996 Jul;28(1):23-31. PubMed PMID: 8712218. 6: Longphre M, Kleeberger SR. Susceptibility to platelet-activating factor-induced airway hyperreactivity and hyperpermeability: interstrain variation and genetic control. Am J Respir Cell Mol Biol. 1995 Nov;13(5):586-94. PubMed PMID: 7576695. 7: Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature. 1995 Oct 5;377(6548):435-8. PubMed PMID: 7566121. 8: Bochnowicz S, Underwood DC. Dose-dependent mediation of leukotriene D4-induced airway microvascular leakage and bronchoconstriction in the guinea pig. Prostaglandins Leukot Essent Fatty Acids. 1995 Jun;52(6):403-11. PubMed PMID: 7644563. 9: Lanese DM, Falk SA, Conger JD. Sequential agonist activation and site-specific mediation of acute cyclosporine constriction in rat renal arterioles. Transplantation. 1994 Dec 27;58(12):1371-8. PubMed PMID: 7809931. 10: Maggi M, Bonaccorsi L, Finetti G, Carloni V, Muratori M, Laffi G, Forti G, Serio M, Baldi E. Platelet-activating factor mediates an autocrine proliferative loop in the endometrial adenocarcinoma cell line HEC-1A. Cancer Res. 1994 Sep 1;54(17):4777-84. PubMed PMID: 7520361. 11: Stoll LL, Denning GM, Kasner NA, Hunninghake GW. Platelet-activating factor may stimulate both receptor-dependent and receptor-independent increases in [Ca2+] in human airway epithelial cells. J Biol Chem. 1994 Feb 11;269(6):4254-9. PubMed PMID: 8307989. 12: Ioculano M, Squadrito F, Altavilla D, Canale P, Campo GM, Bussolino F, Sardella A, Urna G, Caputi AP. Protective effects of L-659,989, a platelet-activating factor receptor antagonist, in myocardial ischemia and reperfusion in rats. J Cardiovasc Pharmacol. 1994 Jan;23(1):7-12. PubMed PMID: 7511738. 13: Ko W, Lang D, Hawes AS, Zelano JA, Isom OW, Krieger KH. Platelet-activating factor antagonism attenuates platelet and neutrophil activation and reduces myocardial injury during coronary reperfusion. J Surg Res. 1993 Nov;55(5):504-15. PubMed PMID: 8231170. 14: Weber C, Aepfelbacher M, Haag H, Ziegler-Heitbrock HW, Weber PC. Tumor necrosis factor induces enhanced responses to platelet-activating factor and differentiation in human monocytic Mono Mac 6 cells. Eur J Immunol. 1993 Apr;23(4):852-9. PubMed PMID: 7681399. 15: Lin Y, Jamieson D. Are leukotrienes or PAF involved in hyperbaric oxygen toxicity? Agents Actions. 1993 Jan;38(1-2):66-75. PubMed PMID: 8386902. 16: Kantar A, Giorgi PL, Fiorini R. Effect of PAF on human lymphocyte membranes: a fluorescence study. Agents Actions. 1993;38 Spec No:C115-7. PubMed PMID: 8317302. 17: Zingarelli B, Squadrito F, Ioculano M, Altavilla D, Bussolino F, Campo GM, Caputi AP. Platelet activating factor interaction with tumor necrosis factor and myocardial depressant factor in splanchnic artery occlusion shock. Eur J Pharmacol. 1992 Nov 3;222(1):13-9. PubMed PMID: 1468489. 18: Tan WC, Bethel RA. The effect of platelet activating factor antagonist on ozone-induced airway inflammation and bronchial hyperresponsiveness in guinea pigs. Am Rev Respir Dis. 1992 Oct;146(4):916-22. PubMed PMID: 1416419. 19: Patel KD, Zimmerman GA, Prescott SM, McIntyre TM. Novel leukocyte agonists are released by endothelial cells exposed to peroxide. J Biol Chem. 1992 Jul 25;267(21):15168-75. PubMed PMID: 1321830. 20: Porras-Reyes BH, Mustoe TA. Platelet-activating factor: improvement in wound healing by a chemotactic factor. Surgery. 1992 Apr;111(4):416-23. Erratum in: Surgery 1992 Sep;112(3):612. PubMed PMID: 1557687.